Prostate cancer intensity-modulated radiotherapy and long term genitourinary toxicity: an evolving therapeutic landscape

[1] Catton CN(2017)Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer J Clin Oncol 35 1884-90

[2] Lukka H(2018)Daily versus weekly prostate cancer image guided radiation therapy: phase 3 multicenter randomized trial Int J Radiat Oncol Biol Phys 102 1420-9

[3] Gu CS(2011)Toxicity and long-term outcomes of dose-escalated intensity modulated radiation therapy to 74Gy for localised prostate cancer in a single Australian centre Cancers 3 3419-31

[4] Martin JM(2016)Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial Lancet Oncol 17 1047-60

[5] Supiot S(2021)Impact of hypofractionated radiotherapy on patient-reported outcomes in prostate cancer: results up to 5 yr in the CHHiP trial (CRUK/06/016) Eur Urol Oncol 4 980-92

[6] Chung PWM(2017)National population-based study comparing treatment-related toxicity in men who received intensity modulated versus 3-dimensional conformal radical radiation therapy for prostate cancer Int J Radiat Oncol Biol Phys 99 1253-60

[7] de Crevoisier R(2022)Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: a combined analysis of 23 prospective clinical trials Int J Radiat Oncol Biol Phys 112 75-82

[8] Bayar MA(2014)Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer Int J Radiat Oncol Biol Phys 88 339-44

[9] Pommier P(2020)Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results Cancer Med 9 3097-106

[10] Muracciole X(2020)A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer Radiother Oncol 142 62-71

[1] Catton CN(2017)Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer J Clin Oncol 35 1884-90

[2] Lukka H(2018)Daily versus weekly prostate cancer image guided radiation therapy: phase 3 multicenter randomized trial Int J Radiat Oncol Biol Phys 102 1420-9

[3] Gu CS(2011)Toxicity and long-term outcomes of dose-escalated intensity modulated radiation therapy to 74Gy for localised prostate cancer in a single Australian centre Cancers 3 3419-31

[4] Martin JM(2016)Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial Lancet Oncol 17 1047-60

[5] Supiot S(2021)Impact of hypofractionated radiotherapy on patient-reported outcomes in prostate cancer: results up to 5 yr in the CHHiP trial (CRUK/06/016) Eur Urol Oncol 4 980-92

[6] Chung PWM(2017)National population-based study comparing treatment-related toxicity in men who received intensity modulated versus 3-dimensional conformal radical radiation therapy for prostate cancer Int J Radiat Oncol Biol Phys 99 1253-60

[7] de Crevoisier R(2022)Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: a combined analysis of 23 prospective clinical trials Int J Radiat Oncol Biol Phys 112 75-82

[8] Bayar MA(2014)Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer Int J Radiat Oncol Biol Phys 88 339-44

[9] Pommier P(2020)Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results Cancer Med 9 3097-106

[10] Muracciole X(2020)A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer Radiother Oncol 142 62-71